The company is releasing the medication in 200 mg/2 mL and 500 mg/5 mL single-dose vials. This launch expands Lupin’s footprint in the competitive U.S. generic space, where the company maintains a broad portfolio spanning respiratory, cardiovascular, and central nervous system therapies. By providing a bioequivalent option to the established Bridion brand, Lupin aims to capture a share of the clinical market for patients aged two years and older.

Lupin operates 15 manufacturing sites and seven research centers worldwide, supporting its distribution network across more than 100 countries. This latest regulatory clearance underscores the company's focus on complex generics and biotechnology, further diversifying its presence in the American healthcare sector.